DexCom, Inc. (NASDAQ:DXCM) – Equities researchers at Piper Jaffray Companies dropped their Q2 2019 earnings per share (EPS) estimates for shares of DexCom in a research report issued to clients and investors on Wednesday, May 1st. Piper Jaffray Companies analyst J. Mckim now forecasts that the medical device company will post earnings per share of ($0.11) for the quarter, down from their prior forecast of $0.02. Piper Jaffray Companies currently has a “Overweight” rating and a $173.00 target price on the stock. Piper Jaffray Companies also issued estimates for DexCom’s FY2019 earnings at $0.52 EPS, Q1 2020 earnings at $0.14 EPS, FY2020 earnings at $1.08 EPS and FY2021 earnings at $1.74 EPS.
Other research analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of DexCom from a “hold” rating to a “buy” rating and set a $138.00 target price on the stock in a report on Monday. Canaccord Genuity upped their target price on shares of DexCom from $140.00 to $160.00 and gave the company a “buy” rating in a report on Friday, February 22nd. ValuEngine lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Monday, April 1st. TheStreet lowered shares of DexCom from a “c” rating to a “d+” rating in a report on Friday, April 5th. Finally, Morgan Stanley upped their target price on shares of DexCom from $135.00 to $160.00 and gave the company an “equal weight” rating in a report on Monday, February 25th. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. DexCom currently has an average rating of “Buy” and a consensus price target of $152.25.
NASDAQ:DXCM opened at $122.21 on Monday. The stock has a market capitalization of $11.19 billion, a price-to-earnings ratio of 407.37 and a beta of 0.73. The company has a debt-to-equity ratio of 1.57, a quick ratio of 7.32 and a current ratio of 7.18. DexCom has a 12-month low of $81.92 and a 12-month high of $156.16.
DexCom (NASDAQ:DXCM) last released its earnings results on Wednesday, May 1st. The medical device company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.12. The company had revenue of $280.50 million for the quarter, compared to analyst estimates of $246.10 million. DexCom had a negative net margin of 11.51% and a positive return on equity of 8.45%. The firm’s quarterly revenue was up 52.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.30) EPS.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its position in DexCom by 1.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 161,295 shares of the medical device company’s stock worth $23,073,000 after purchasing an additional 1,758 shares in the last quarter. Legal & General Group Plc increased its position in DexCom by 42.6% during the 3rd quarter. Legal & General Group Plc now owns 60,492 shares of the medical device company’s stock worth $8,653,000 after purchasing an additional 18,075 shares in the last quarter. Vanguard Group Inc increased its position in DexCom by 11.5% during the 3rd quarter. Vanguard Group Inc now owns 7,942,861 shares of the medical device company’s stock worth $1,136,147,000 after purchasing an additional 816,247 shares in the last quarter. Great Lakes Advisors LLC acquired a new stake in DexCom during the 3rd quarter worth approximately $243,000. Finally, Marshall Wace North America L.P. increased its position in DexCom by 64.5% during the 3rd quarter. Marshall Wace North America L.P. now owns 31,692 shares of the medical device company’s stock worth $4,533,000 after purchasing an additional 12,431 shares in the last quarter. 96.88% of the stock is owned by institutional investors.
In other news, EVP Steven Robert Pacelli sold 3,596 shares of the company’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $116.61, for a total transaction of $419,329.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Patrick Michael Murphy sold 400 shares of the company’s stock in a transaction dated Friday, February 8th. The shares were sold at an average price of $142.76, for a total transaction of $57,104.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 96,530 shares of company stock valued at $13,467,422. Corporate insiders own 1.80% of the company’s stock.
About DexCom
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient’s mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.